<DOC>
	<DOCNO>NCT02980874</DOCNO>
	<brief_summary>This Phase 3 , multicenter , randomize , mask , control , parallel group study 12 month duration treatment naïve subject RVO .</brief_summary>
	<brief_title>Suprachoroidal Injection Triamcinolone Acetonide With IVT Aflibercept Subjects With Macular Edema Following RVO</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<criteria>Has clinical diagnosis RVO study eye Has CST ≥ 300 µm study eye Has ETDRS BCVA score ≥ 5 letter read ≤ 70 letter read study eye ; Is naïve local pharmacologic treatment RVO study eye ; Any active ocular disease infection study eye RVO Intraocular pressure &gt; 22mmHg uncontrolled glaucoma study eye Any uncontrolled systemic disease , opinion Investigator , would preclude participation study Any evidence neovascularization study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>RVO</keyword>
	<keyword>ME</keyword>
	<keyword>Central Subfield Thickness</keyword>
	<keyword>OCT</keyword>
	<keyword>Optical Coherence Tomography</keyword>
	<keyword>Cystoid Macular Edema</keyword>
	<keyword>Subretinal Fluid</keyword>
	<keyword>Eylea</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Anti-VEGF</keyword>
	<keyword>Suprachoroidal</keyword>
</DOC>